Monoclonal antibodies have had their impact on biochemical research for more than a decade. Besides their exuberant use as reagents, quite a number of diagnostic and therapeutic approaches have been followed, and an impressive number of technological improvements, e.g. humanization, recombinant miniantibodies, have been elaborated to strengthen the principles. With respect to clinical applications, the first generation of antibody "drugs" is yielding promising results while second and third generation antibody constructs are already underway. This book reviews the status of technological development and brings this into the perspective of clinical results. A rapidly growing amount of clinical data is collected in an expanding number of indications. Hence, the review of clinical study results has been grouped according to the fields of oncology and of chronic and acute inflammation.
Recombinant antibodies - construction and production; bispecific antibodies; targeted cytotoxicity - antibody-drug conjugates and antibody-toxins; selective drug delivery using targeted enzymes for prodrug activation; immunoscintigraphy and radioimmunotherapy; clinical studies in oncology; clinical studies and chronic inflammation; marrow purging and stem cell preparation.